David Tai

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Robin Kate Kelley, Bruno Sangro, William Proctor Harris et al. · Journal of Clinical Oncology · 2021 · 427 citations · Full text

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et al. · Clinical Cancer Research · 2021 · 335 citations · Full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng et al. · Annals of Oncology · 2020 · 233 citations

Hepatology, Medicine, Cancer Management +11

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

Belinda Lee, Lara Lipton, Joshua D. Cohen et al. · Annals of Oncology · 2019 · 206 citations · Full text

Surgical Oncology, Pancreatic Cancer, Gastrointestinal Oncology +9

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

Martin Schüler, Byoung Chul Cho, Cyrus Sayehli et al. · The Lancet Oncology · 2019 · 161 citations

Fgfr Mrna Expression, Oncology, Medicine +8